Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
21,429
Total Claims
$2.2M
Drug Cost
761
Beneficiaries
$2,828
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-90%
Opioid rate vs peers
0.2% vs 2.2% avg
+100%
Cost per patient vs peers
$2,828 vs $1,411 avg
+65%
Brand preference vs peers
17.5% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.2%
Opioid Rate
46
Opioid Claims
$494
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,673 claims · $1.8M
Generic: 17,291 claims · $354K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 237 | $219K |
| Apixaban | 184 | $164K |
| Insulin Glargine,hum.Rec.Anlog | 205 | $97K |
| Rivaroxaban | 86 | $94K |
| Empagliflozin | 116 | $94K |
| Dulaglutide | 62 | $73K |
| Empagliflozin/Linagliptin | 94 | $71K |
| Sitagliptin Phos/Metformin Hcl | 81 | $71K |
| Insulin Lispro | 97 | $70K |
| Sitagliptin Phos/Metformin Hcl | 86 | $69K |
| Levothyroxine Sodium | 646 | $64K |
| Dapagliflozin Propanediol | 79 | $62K |
| Empaglifloz/Linaglip/Metformin | 100 | $58K |
| Insulin Nph Hum/Reg Insulin Hm | 131 | $56K |
| Insulin Glargine,hum.Rec.Anlog | 83 | $43K |
Prescribing Profile
Patient Profile
73
Avg Age
58%
Female
1.88
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data